Home › Triple-Negative Breast Cancer › Kentucky › Louisville
Triple-Negative Breast Cancer clinical trials in Louisville, KY
3 studies for Triple-Negative Breast Cancer are looking for participants at sites in and around Louisville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RecruitingPhase 1
- Norton Cancer Institute, Louisville
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RecruitingPhase 3
- Norton Healthcare, Inc., Louisville
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RecruitingPhase 1
- Norton Cancer Institute /ID# 248903, Louisville
Triple-Negative Breast Cancer trials in other cities
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Arlington, VA20 studies
- Atlanta, GA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
Other studies in Louisville
- Non-Small Cell Lung Cancer22 studies
- Obesity17 studies
- Overweight15 studies
- Cancer (all types)14 studies
- Heart Failure13 studies
- Acute Myeloid Leukemia12 studies
- Multiple Myeloma12 studies
- Ovarian Cancer12 studies
- Breast Cancer11 studies
- Head and Neck Squamous Cell Carcinoma11 studies
- Lung Cancer11 studies
- Melanoma10 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.